申请人:Hoffmann-La Roche Inc.
公开号:US06130239A1
公开(公告)日:2000-10-10
Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.
本发明涉及一种新型的4-烯基和4-炔基吲哚,其化学式为##STR1##以及其药学上可接受的盐,其中R.sup.1,R.sup.2,R.sup.3,a,b和X的定义如本文所述。这些化合物抑制细胞周期依赖性激酶(CDKs),特别是CDK2。这些化合物及其药学上可接受的盐和前药是抗增殖剂,用于治疗或控制细胞增殖性疾病,特别是癌症,更特别是用于治疗或控制乳腺和结肠肿瘤。本发明还涉及包含化合物I和II的制药组合物,以及用于制备化合物I和II的中间体。